BRPI0818575A2 - Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo - Google Patents

Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo

Info

Publication number
BRPI0818575A2
BRPI0818575A2 BRPI0818575-1A2A BRPI0818575A BRPI0818575A2 BR PI0818575 A2 BRPI0818575 A2 BR PI0818575A2 BR PI0818575 A BRPI0818575 A BR PI0818575A BR PI0818575 A2 BRPI0818575 A2 BR PI0818575A2
Authority
BR
Brazil
Prior art keywords
colorform
modifying
compound
same
solid state
Prior art date
Application number
BRPI0818575-1A2A
Other languages
English (en)
Inventor
Todd F Ovokaitys
John Scott Strachan
Original Assignee
Todd F Ovokaitys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Todd F Ovokaitys filed Critical Todd F Ovokaitys
Publication of BRPI0818575A2 publication Critical patent/BRPI0818575A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
BRPI0818575-1A2A 2007-10-17 2008-10-16 Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo BRPI0818575A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99944507P 2007-10-17 2007-10-17
US99948307P 2007-10-17 2007-10-17
US99946207P 2007-10-17 2007-10-17
PCT/US2008/080095 WO2009052246A1 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US12/252,458 US8173632B2 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same

Publications (1)

Publication Number Publication Date
BRPI0818575A2 true BRPI0818575A2 (pt) 2014-10-07

Family

ID=40567777

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818575-1A2A BRPI0818575A2 (pt) 2007-10-17 2008-10-16 Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo

Country Status (10)

Country Link
US (1) US8173632B2 (pt)
EP (1) EP2211611B1 (pt)
JP (1) JP5596547B2 (pt)
CN (1) CN101969766B (pt)
BR (1) BRPI0818575A2 (pt)
CA (1) CA2702903C (pt)
EA (1) EA023338B1 (pt)
IL (1) IL205155A (pt)
WO (1) WO2009052246A1 (pt)
ZA (1) ZA201003353B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027333B1 (ru) * 2007-10-17 2017-07-31 Тодд Ф. Овокайтис Стабильный при комнатной температуре некристаллический аспирин
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
CN103360357B (zh) * 2013-08-07 2015-07-22 中国药科大学 辛伐他丁格列齐特共无定型物
CN104415042A (zh) * 2013-08-30 2015-03-18 天津药物研究院 一种共无定型系统及其制备方法
CN103923049A (zh) * 2014-05-05 2014-07-16 武汉远瞩医药科技有限公司 黄芩素咖啡因共无定型物
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP2017071559A (ja) * 2015-10-05 2017-04-13 学校法人大阪医科薬科大学 トラニラスト−ジフェンヒドラミンのコアモルファス
US11453840B2 (en) * 2018-04-28 2022-09-27 John Anton Broadhurst Method for applying energy to cannabidiol
WO2020262455A1 (ja) * 2019-06-25 2020-12-30 味の素株式会社 共非晶質構造を有するアミノ酸混合物
CA3201604A1 (en) 2020-12-08 2022-06-16 Todd Frank OVOKAITYS Methods and systems for increased production of stem cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525103D0 (en) * 1995-12-08 1996-02-07 Strachan John S Optical device and method of manufacture
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
IT1312115B1 (it) * 1999-06-24 2002-04-04 Nicox Sa Composti amorfi e relative composizioni farmaceutiche
GB9920351D0 (en) * 1999-08-28 1999-11-03 Strachen John S Sparse constructive node stimulation of cell surface molecular resonance in vivo
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
CZ292832B6 (cs) 2001-08-30 2003-12-17 Ivax Pharmaceuticals S.R.O. Způsob přípravy silymarinu se zvýšenou rozpustností
EP1444041A2 (en) * 2001-09-21 2004-08-11 Solvias AG Sealing system with flow channels
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2004211978A1 (en) * 2003-02-10 2004-08-26 Todd Ovokaitys Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
EP1898911A1 (en) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
WO2007100614A2 (en) * 2006-02-24 2007-09-07 Scidose, Llc STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR

Also Published As

Publication number Publication date
ZA201003353B (en) 2011-12-28
IL205155A0 (en) 2010-11-30
US20090131376A1 (en) 2009-05-21
EP2211611A4 (en) 2012-03-28
CA2702903C (en) 2016-01-19
EA023338B1 (ru) 2016-05-31
US8173632B2 (en) 2012-05-08
IL205155A (en) 2017-12-31
CN101969766B (zh) 2015-05-06
EP2211611A1 (en) 2010-08-04
JP5596547B2 (ja) 2014-09-24
CN101969766A (zh) 2011-02-09
JP2011500709A (ja) 2011-01-06
WO2009052246A1 (en) 2009-04-23
EA201070467A1 (ru) 2011-06-30
EP2211611B1 (en) 2014-12-10
CA2702903A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812481A2 (pt) Composição aquosa, processo para a fabricação da composição aquosa, uso da composição aquosa, e, processo para a produção de epicloridrina
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0920920A2 (pt) processo para dessulfuração
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
DK1858488T3 (da) Tigecyclinsammensætninger samt fremstillingsfremgangsmåder
BRPI0914083A2 (pt) "painél compósito e processo para fabricar um painél compósito"
BRPI0821354A2 (pt) Processo para a preparação de fipronil e de análogos do mesmo
PT2201156E (pt) Composição biocombustível e processo de fabrico
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0810850A2 (pt) Processo para carbonilação de dimetil éter
BRPI0810846A2 (pt) Processo para carbonilção de dimetil éter
BRPI0909393A2 (pt) processo para a preparação de polibutadieno
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
ZA201003353B (en) Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0913243A2 (pt) processo para a fabricação de 1, 2-dicloroetano e de pelo menos um composto derivado de etileno
BRPI0912163A2 (pt) Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico.
BRPI0718999A2 (pt) Pirazois substituídos, composições que os contêm, processo de produção e utilização
BRPI0717924A2 (pt) Processo contínuo para monoalquilar um composto aromático
BRPI0821837A2 (pt) Processo para a preparação de 6-substituídas-1-(2h)-isoquinolinonas
BRPI0820926A2 (pt) Composição de poliolefina, mistura-padrão, processo para produzir um artigo, artigo, uso de uma composição de poliolefina e de um composto contendo silício
BR112012003775A2 (pt) processo para a preparação de um composto, composto e composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.